生物类似药标准干扰素与聚乙二醇干扰素治疗慢性丙型肝炎基因型 2 或 3 的疗效比较。

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.

机构信息

Viral Hepatitis Study Group, Universidade Estadual de Campinas, Campinas, SP, Brazil.

出版信息

Braz J Infect Dis. 2012 May-Jun;16(3):232-6.

Abstract

BACKGROUND

Pegylated interferon (Peg-IFN) and standard interferon (IFN) play a significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard IFN is widely available in Brazil for the treatment of HCV infection genotypes 2 or 3, but its efficacy compared to Peg-IFN is unknown.

OBJECTIVE

To compare the sustained virological response (SVR) rates following treatment with biosimilar standard IFN plus ribavirin (RBV) versus Peg-IFN plus RBV in patients with HCV genotypes 2 or 3 infection.

METHODS

A retrospective cohort study was conducted in patients with HCV genotypes 2 or 3 infection treated with biosimilar standard IFN plus RBV or with Peg-IFN plus RBV. SVR rates of the two treatments were compared.

RESULTS

From January 2005 to December 2010, 172 patients with a mean age of 44 +/- 9.3 years were included. There were eight (4.7%) patients with HCV genotype 2 infections. One hundred fourteen (66.3%) were treated with biosimilar standard IFN plus RBV, whist 58 (33.7%) patients were treated with Peg-IFN plus RBV. Between the two groups, there were no significant differences regarding age, gender, glucose level, platelet count, hepatic necroinflammatory grade, and hepatic fibrosis stage. Overall, 59.3% (102/172) patients had SVR. In patients treated with Peg-IFN plus RBV, 79.3% (46/58) had SVR compared to 49.1% (56/114) among those treated with biosimilar standard IFN plus RBV (p = 0.0001).

CONCLUSION

In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV.

摘要

背景

聚乙二醇干扰素（Peg-IFN）和标准干扰素（IFN）在治疗丙型肝炎病毒（HCV）感染中发挥着重要作用。巴西广泛提供生物类似标准 IFN 用于治疗 HCV 基因型 2 或 3 感染，但与 Peg-IFN 相比，其疗效尚不清楚。

目的

比较生物类似标准 IFN 联合利巴韦林（RBV）与 Peg-IFN 联合 RBV 治疗 HCV 基因型 2 或 3 感染患者的持续病毒学应答（SVR）率。

方法

对 HCV 基因型 2 或 3 感染患者进行回顾性队列研究，这些患者接受了生物类似标准 IFN 联合 RBV 或 Peg-IFN 联合 RBV 治疗。比较两种治疗方法的 SVR 率。

结果

2005 年 1 月至 2010 年 12 月，共纳入 172 例平均年龄为 44 ± 9.3 岁的患者。其中有 8 例（4.7%）患者为 HCV 基因型 2 感染。114 例（66.3%）患者接受了生物类似标准 IFN 联合 RBV 治疗，58 例（33.7%）患者接受了 Peg-IFN 联合 RBV 治疗。两组患者在年龄、性别、血糖水平、血小板计数、肝坏死性炎症分级和肝纤维化分期等方面均无显著差异。总体而言，172 例患者中有 59.3%（102/172）患者获得了 SVR。在接受 Peg-IFN 联合 RBV 治疗的患者中，79.3%（46/58）患者获得了 SVR，而接受生物类似标准 IFN 联合 RBV 治疗的患者中 SVR 率为 49.1%（56/114）（p=0.0001）。